Emerging Phase III Data Validate Clinical Trial Design In Lupus
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Over a span of little more than a month this summer, the face of clinical trials for lupus drugs changed considerably for the better.
You may also be interested in...
How A Biomarker Revived Synta’s Cancer Drug Elesclomol
Using a simple, cheap, available enzyme test, Synta Pharmaceuticals Corp. has been able to rescue the development program for its oncology candidate elesclomol after a high-profile Phase III failure in melanoma.
How A Biomarker Revived Synta’s Cancer Drug Elesclomol
Using a simple, cheap, available enzyme test, Synta Pharmaceuticals Corp. has been able to rescue the development program for its oncology candidate elesclomol after a high-profile Phase III failure in melanoma.
Late-Stage Lupus Therapies Glow In Halo Of Benlysta Spotlight
If Human Genome Sciences/GlaxoSmithKline’s Benlysta (belimumab) succeeds in becoming the first new lupus therapy in half a century to make it through the regulatory gauntlet, it could change not only the commercial outlook in the lupus market, but also the landscape of future lupus clinical trial design.